CellaVision ABCHIX:CEVIS 93 Graham Number is kr44.65 as of Mar. 2026, which is 100% below its 10-year median of 6.83. GuruFocus rates CHIX:CEVIS with a GF Score™ of 93/100 and a GF Value™ of kr231.79. The stock has 1 warning sign investors should review. Among 399 Medical Devices & Instruments companies, CellaVision AB ranks worse than 74.19% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-11), the stock price of CellaVision AB is kr160.20. CellaVision AB's graham number for the quarter that ended in Mar. 2026 was kr44.65. Therefore, CellaVision AB's Price to Graham Number ratio for today is 3.59.
The historical rank and industry rank for CellaVision AB's Graham Number or its related term are showing as below:
CHIX:CEVIs'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.08 Med: 6.83 Max: 23.1
Current: 3.28
During the past 13 years, the highest Price to Graham Number ratio of CellaVision AB was 23.10. The lowest was 3.08. And the median was 6.83.
CHIX:CEVIs's Price-to-Graham-Number is ranked worse than 74.19% of 399
companies
in the Medical Devices & Instruments industry
Industry Median: 1.75
vs CHIX:CEVIs: 3.28
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
CellaVision AB (CHIX:CEVIs) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
CellaVision AB's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
160.20
/
44.65
=
3.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
CellaVision AB Graham Number Related Terms
CellaVision AB Graham Number Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CEVIS vs ABT, SYK, MDT: Graham Number Comparison
For the Medical Devices subindustry, CellaVision AB's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CHIX:CEVIS) has a Graham Number of kr44.65 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on CellaVision AB and its competitors. This is 554% above median its historical median of 6.83. Over the past decade, CellaVision AB's Graham Number has ranged from 3.08 to 23.10. According to the industry distribution chart, CellaVision AB ranks #296 out of 399 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is CellaVision AB's Graham Number too high?
CellaVision AB's current Graham Number of kr44.65 is 554% above median its 10-year median of 6.83. Over the past 10 years, this metric has ranged from a low of 3.08 to a high of 23.10. Based on the distribution chart, CellaVision AB ranks #296 out of 399 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #296 out of 399 companies for Graham Number. This places CellaVision AB in the lower half of its industry. The industry median Graham Number is 1.75. Historically, CellaVision AB's own Graham Number has ranged from 3.08 to 23.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.75, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Graham Number is kr44.65, which is 554% above median its own 10-year median of 6.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Graham Number of kr44.65. The stock's GF Value™ is kr231.79, compared to a current price of kr160.20 — trading 30.9% below its estimated fair value. The current Graham Number is kr44.65, which is 554% above median its 10-year median of 6.83. CellaVision AB's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Graham Number is kr44.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 30.9% below its estimated GF Value™ of kr231.79.
Key valuation signals for CHIX:CEVIS:
Graham Number: kr44.65 (554% above median its 10-year median of 6.83)
GF Value™: kr231.79 vs. price of kr160.20 (30.9% below fair value)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
93GF Score
Get the complete analysis for CHIX:CEVIS
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
